These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 27810556)
1. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556 [TBL] [Abstract][Full Text] [Related]
2. ATB Luo Q; Yang B; Tao W; Li J; Kou L; Lian H; Che X; He Z; Sun J Biomater Sci; 2017 Jan; 5(2):295-304. PubMed ID: 27991616 [TBL] [Abstract][Full Text] [Related]
3. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid. Li J; Xu H; Ke X; Tian J J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855 [TBL] [Abstract][Full Text] [Related]
4. Endocytosis of ATB Kou L; Huang H; Lin X; Jiang X; Wang Y; Luo Q; Sun J; Yao Q; Ganapathy V; Chen R Expert Opin Drug Deliv; 2020 Mar; 17(3):395-405. PubMed ID: 31990587 [No Abstract] [Full Text] [Related]
5. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB Wang Z; Chi D; Wu X; Wang Y; Lin X; Xu Z; Liu H; Sun J; He Z; Wang Y J Control Release; 2019 Dec; 316():22-33. PubMed ID: 31676386 [TBL] [Abstract][Full Text] [Related]
6. Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. Hatanaka T; Haramura M; Fei YJ; Miyauchi S; Bridges CC; Ganapathy PS; Smith SB; Ganapathy V; Ganapathy ME J Pharmacol Exp Ther; 2004 Mar; 308(3):1138-47. PubMed ID: 14617696 [TBL] [Abstract][Full Text] [Related]
7. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting. Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582 [TBL] [Abstract][Full Text] [Related]
8. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation. Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122 [TBL] [Abstract][Full Text] [Related]
9. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice. Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241 [TBL] [Abstract][Full Text] [Related]
10. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745 [TBL] [Abstract][Full Text] [Related]
11. Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. Patel K; Doddapaneni R; Sekar V; Chowdhury N; Singh M Mol Pharm; 2016 Jun; 13(6):2049-58. PubMed ID: 27070720 [TBL] [Abstract][Full Text] [Related]
12. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo. Luo Y; Liu Z; Zhang X; Huang J; Yu X; Li J; Xiong D; Sun X; Zhong Z Int J Nanomedicine; 2016; 11():3111-29. PubMed ID: 27471381 [TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076 [TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Vivo Evaluation of SP94 Modified Liposomes Loaded with N-14NCTDA, a Norcantharimide Derivative for Hepatocellular Carcinoma-Targeting. Jiang Y; Liu X; Tan X; Hou Y; Sun W; Gou J; Yin T; He H; Zhang Y; Tang X AAPS PharmSciTech; 2020 Oct; 21(7):277. PubMed ID: 33033942 [TBL] [Abstract][Full Text] [Related]
15. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting. Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386 [TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-hepatocarcinoma efficacy by GLUT1 targeting and cellular microenvironment-responsive PAMAM-camptothecin conjugate. Ma P; Sun Y; Chen J; Li H; Zhu H; Gao X; Bi X; Zhang Y Drug Deliv; 2018 Nov; 25(1):153-165. PubMed ID: 29282992 [TBL] [Abstract][Full Text] [Related]
17. Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo. Zhang J; Yang C; Pan S; Shi M; Li J; Hu H; Qiao M; Chen D; Zhao X Drug Deliv; 2018 Nov; 25(1):723-737. PubMed ID: 29513049 [TBL] [Abstract][Full Text] [Related]
18. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193 [TBL] [Abstract][Full Text] [Related]
19. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine. Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323 [TBL] [Abstract][Full Text] [Related]
20. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Li L; Di X; Zhang S; Kan Q; Liu H; Lu T; Wang Y; Fu Q; Sun J; He Z Colloids Surf B Biointerfaces; 2016 May; 141():260-267. PubMed ID: 26859117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]